Abstract
Members of the solute carrier (SLC) family of transporters are responsible for the cellular influx of a broad range of endogenous compounds and xenobiotics. These proteins are highly expressed in the gastrointestinal tract and eliminating organs such as the liver and kidney, and are considered to be of particular importance in governing drug absorption and elimination. Many of the same transporters are also expressed in a wide variety of organs targeted by clinically important anticancer drugs, directly affect cellular sensitivity to these agents, and indirectly influence treatment-related side effects. Furthermore, targeted intervention strategies involving the use of transport inhibitors have been recently developed, and have provided promising lead candidates for combinatorial therapies associated with decreased toxicity. Gaining a better understanding of the complex interplay between transporter-mediated on-target and off-target drug disposition will help guide the further development of these novel treatment strategies to prevent drug accumulation in toxicity-associated organs, and improve the safety of currently available treatment modalities. In this report, we provide an update on this rapidly emerging field with particular emphasis on anticancer drugs belonging to the classes of taxanes, platinum derivatives, nucleoside analogs, and anthracyclines.
A.S. and S.H. originated the concept, J.A. wrote the paper, all authors contributed to manuscript review and editing, and all authors approved the final version.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abraham JE, Guo Q, Dorling L, Tyrer J, Ingle S, Hardy R, Vallier AL, Hiller L, Burns R, Jones L, Bowden SJ, Dunn JA, Poole CJ, Caldas C, Pharoah PP, Earl HM (2014) Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel. Clin Cancer Res 20(9):2466–2475. https://doi.org/10.1158/1078-0432.CCR-13-3232
Albers JW, Chaudhry V, Cavaletti G, Donehower RC (2014) Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 3(3):CD005228. https://doi.org/10.1002/14651858.CD005228.pub4
Anderson JT, Hu S, Fu Q, Baker SD, Sparreboom A (2019) Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice. Pharmacol Res Perspect 7(6):e00534. https://doi.org/10.1002/prp2.534
Andreev E, Brosseau N, Carmona E, Mes-Masson AM, Ramotar D (2016) The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicin. Sci Rep 6:20508. https://doi.org/10.1038/srep20508
Arany I, Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23(5):460–464
Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP (2008) A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 34(4):368–377. https://doi.org/10.1016/j.ctrv.2008.01.003
Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, Alberti P, Bergamo F, Cortinovis D, Cazzaniga M, Santos C, Papadimitriou K, Kalofonos HP (2013) Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer 119(2):438–444. https://doi.org/10.1002/cncr.27732
Atilano-Roque A, Joy MS (2017) Characterization of simvastatin acid uptake by organic anion transporting polypeptide 3A1 (OATP3A1) and influence of drug-drug interaction. Toxicol In Vitro 45(Pt 1):158–165. https://doi.org/10.1016/j.tiv.2017.09.002
Ayala-Lopez N, Jackson WF, Burnett R, Wilson JN, Thompson JM, Watts SW (2015) Organic cation transporter 3 contributes to norepinephrine uptake into perivascular adipose tissue. Am J Physiol Heart Circ Physiol 309(11):H1904–H1914. https://doi.org/10.1152/ajpheart.00308.2015
Ayla S, Seckin I, Tanriverdi G, Cengiz M, Eser M, Soner BC, Oktem G (2011) Doxorubicin induced nephrotoxicity: protective effect of nicotinamide. Int J Cell Biol 2011:390238. https://doi.org/10.1155/2011/390238
Bachmakov I, Glaeser H, Endress B, Morl F, Konig J, Fromm MF (2009) Interaction of beta-blockers with the renal uptake transporter OCT2. Diabetes Obes Metab 11(11):1080–1083. https://doi.org/10.1111/j.1463-1326.2009.01076.x
Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A (2009) Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 85(2):155–163. https://doi.org/10.1038/clpt.2008.95
Baldwin SA, Mackey JR, Cass CE, Young JD (1999) Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today 5(5):216–224. https://doi.org/10.1016/S1357-4310(99)01459-8
Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL (2012) A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 18(18):5099–5109. https://doi.org/10.1158/1078-0432.CCR-12-1590
Ban M, Hettich D, Huguet N (1994) Nephrotoxicity mechanism of cis-platinum (II) diamine dichloride in mice. Toxicol Lett 71(2):161–168
Belum VR, Wu S, Lacouture ME (2013) Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Investig New Drugs 31(4):1078–1086. https://doi.org/10.1007/s10637-013-9977-0
Bergmann TK, Vach W, Feddersen S, Eckhoff L, Green H, Herrstedt J, Brosen K (2013) GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. Acta Oncol 52(4):871–874. https://doi.org/10.3109/0284186X.2012.707787
Berns JS, Ford PA (1997) Renal toxicities of antineoplastic drugs and bone marrow transplantation. Semin Nephrol 17(1):54–66
Boehmerle W, Huehnchen P, Peruzzaro S, Balkaya M, Endres M (2014) Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl/6 mice. Sci Rep 4:6370. https://doi.org/10.1038/srep06370
Boora GK, Kanwar R, Kulkarni AA, Abyzov A, Sloan J, Ruddy KJ, Banck MS, Loprinzi CL, Beutler AS (2016) Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance). Cancer Med 5(4):631–639. https://doi.org/10.1002/cam4.625
Borst P, Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537–592. https://doi.org/10.1146/annurev.biochem.71.102301.093055
Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92(16):1295–1302
Botchkarev VA, Paus R (2003) Molecular biology of hair morphogenesis: development and cycling. J Exp Zool B Mol Dev Evol 298(1):164–180. https://doi.org/10.1002/jez.b.33
Boucek RJ Jr, Dodd DA, Atkinson JB, Oquist N, Olson RD (1997) Contractile failure in chronic doxorubicin-induced cardiomyopathy. J Mol Cell Cardiol 29(10):2631–2640
Brewer JR, Morrison G, Dolan ME, Fleming GF (2016) Chemotherapy-induced peripheral neuropathy: current status and progress. Gynecol Oncol 140(1):176–183. https://doi.org/10.1016/j.ygyno.2015.11.011
Bronchud MH, Margison JM, Howell A, Lind M, Lucas SB, Wilkinson PM (1990) Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer. Cancer Chemother Pharmacol 25(6):435–439. https://doi.org/10.1007/bf00686055
Brosseau N, Andreev E, Ramotar D (2015) Complementation of the yeast model system reveals that Caenorhabditis elegans OCT-1 is a functional transporter of anthracyclines. PLoS One 10(7):e0133182. https://doi.org/10.1371/journal.pone.0133182
Carozzi VA, Canta A, Chiorazzi A (2015) Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett 596:90–107. https://doi.org/10.1016/j.neulet.2014.10.014
Caterson R, Etheredge S, Snitch P, Duggin G (1983) Mechanisms of renal excretion of cisdichlorodiamine platinum. Res Commun Chem Pathol Pharmacol 41(2):255–264
Cavaletti G, Cavalletti E, Oggioni N, Sottani C, Minoia C, D’Incalci M, Zucchetti M, Marmiroli P, Tredici G (2000) Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology 21(3):389–393
Cavaletti G, Tredici G, Petruccioli MG, Donde E, Tredici P, Marmiroli P, Minoia C, Ronchi A, Bayssas M, Etienne GG (2001) Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 37(18):2457–2463. https://doi.org/10.1016/s0959-8049(01)00300-8
Chae YK, Arya A, Malecek MK, Shin DS, Carneiro B, Chandra S, Kaplan J, Kalyan A, Altman JK, Platanias L, Giles F (2016) Repurposing metformin for cancer treatment: current clinical studies. Oncotarget 7(26):40767–40780. https://doi.org/10.18632/oncotarget.8194
Chen M, Neul C, Schaeffeler E, Frisch F, Winter S, Schwab M, Koepsell H, Hu S, Laufer S, Baker SD, Sparreboom A, Nies AT (2020) Sorafenib activity and disposition in liver cancer does not depend on organic cation transporter 1. Clin Pharmacol Ther 107(1):227–237. https://doi.org/10.1002/cpt.1588
Chester JD, Joel SP, Cheeseman SL, Hall GD, Braun MS, Perry J, Davis T, Button CJ, Seymour MT (2003) Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer. J Clin Oncol 21(6):1125–1132. https://doi.org/10.1200/JCO.2003.08.049
Cho SK, Chung JY (2016) The MATE1 rs2289669 polymorphism affects the renal clearance of metformin following ranitidine treatment. Int J Clin Pharmacol Ther 54(4):253–262. https://doi.org/10.5414/CP202473
Cho SK, Kim CO, Park ES, Chung JY (2014) Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers. Br J Clin Pharmacol 78(6):1426–1432. https://doi.org/10.1111/bcp.12476
Christensen MM, Hojlund K, Hother-Nielsen O, Stage TB, Damkier P, Beck-Nielsen H, Brosen K (2015) Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. Eur J Clin Pharmacol 71(6):691–697. https://doi.org/10.1007/s00228-015-1853-8
Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstadt H, Lanvers-Kaminsky C, am Zehnhoff-Dinnesen A, Schinkel AH, Koepsell H, Jurgens H, Schlatter E (2010) Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 176(3):1169–1180. https://doi.org/10.2353/ajpath.2010.090610
Cotsarelis G (2006) Epithelial stem cells: a folliculocentric view. J Invest Dermatol 126(7):1459–1468. https://doi.org/10.1038/sj.jid.5700376
Daley-Yates PT, McBrien DC (1985) The renal fractional clearance of platinum antitumour compounds in relation to nephrotoxicity. Biochem Pharmacol 34(9):1423–1428
Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, Cass CE (2003) Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22(47):7524–7536. https://doi.org/10.1038/sj.onc.1206952
Dasari S, Bernard Tchounwou P (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740C:364–378. https://doi.org/10.1016/j.ejphar.2014.07.025
de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, de Bruijn P, Hu S, Gibson AA, Bruun GH, Corydon TJ, Mikkelsen TS, Walker AL, Du G, Loos WJ, van Schaik RH, Baker SD, Mathijssen RH, Sparreboom A (2012) Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res 18(16):4433–4440. https://doi.org/10.1158/1078-0432.CCR-12-0761
de Graan AJ, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B, de Raaf PJ, de Bruijn P, Engels FK, Eskens FA, Wiemer EA, Verweij J, Mathijssen RH, van Schaik RH (2013) CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin Cancer Res 19(12):3316–3324. https://doi.org/10.1158/1078-0432.CCR-12-3786
De Iuliis F, Taglieri L, Salerno G, Lanza R, Scarpa S (2015) Taxane induced neuropathy in patients affected by breast cancer: literature review. Crit Rev Oncol Hematol 96(1):34–45. https://doi.org/10.1016/j.critrevonc.2015.04.011
de Jong FA, Kitzen JJ, de Bruijn P, Verweij J, Loos WJ (2006) Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain. Cancer Biol Ther 5(9):1105–1110
de Jongh FE, van Veen RN, Veltman SJ, de Wit R, van der Burg ME, van den Bent MJ, Planting AS, Graveland WJ, Stoter G, Verweij J (2003) Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 88(8):1199–1206. https://doi.org/10.1038/sj.bjc.6600884
de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S (2018) Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet 57(10):1229–1254. https://doi.org/10.1007/s40262-018-0644-7
DeGorter MK, Xia CQ, Yang JJ, Kim RB (2012) Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol 52:249–273. https://doi.org/10.1146/annurev-pharmtox-010611-134529
Di Paolo A, Bocci G, Polillo M, Del Re M, Di Desidero T, Lastella M, Danesi R (2011) Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity. Curr Drug Metab 12(10):932–943. https://doi.org/10.2174/138920011798062283
dos Santos NA, Carvalho Rodrigues MA, Martins NM, dos Santos AC (2012) Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol 86(8):1233–1250. https://doi.org/10.1007/s00204-012-0821-7
Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL (2005) Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 23(34):8597–8605. https://doi.org/10.1200/JCO.2005.02.5841
Drenberg CD, Baker SD, Sparreboom A (2013) Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors. Clin Pharmacol Ther 93(3):215–219. https://doi.org/10.1038/clpt.2012.247
Drenberg CD, Paugh SW, Pounds SB, Shi L, Orwick SJ, Li L, Hu S, Gibson AA, Ribeiro RC, Rubnitz JE, Evans WE, Sparreboom A, Baker SD (2015) Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.315
Drenberg CD, Gibson AA, Pounds SB, Shi L, Rhinehart DP, Li L, Hu S, Du G, Nies AT, Schwab M, Pabla N, Blum W, Gruber TA, Baker SD, Sparreboom A (2017) OCTN1 is a high-affinity carrier of nucleoside analogues. Cancer Res 77(8):2102–2111. https://doi.org/10.1158/0008-5472.CAN-16-2548
Drenberg CD, Shelat A, Dang J, Cotton A, Orwick SJ, Li M, Jeon JY, Fu Q, Buelow DR, Pioso M, Hu S, Inaba H, Ribeiro RC, Rubnitz JE, Gruber TA, Guy RK, Baker SD (2019) A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. Nat Commun 10(1):2189. https://doi.org/10.1038/s41467-019-09917-0
Durmus S, Naik J, Buil L, Wagenaar E, van Tellingen O, Schinkel AH (2014) In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters. Int J Cancer 135(7):1700–1710. https://doi.org/10.1002/ijc.28797
Durmus S, Lozano-Mena G, van Esch A, Wagenaar E, van Tellingen O, Schinkel AH (2015) Preclinical mouse models to study human OATP1B1- and OATP1B3-mediated drug-drug interactions in vivo. Mol Pharm 12(12):4259–4269. https://doi.org/10.1021/acs.molpharmaceut.5b00453
Duval M, Daniel SJ (2012) Meta-analysis of the efficacy of amifostine in the prevention of cisplatin ototoxicity. J Otolaryngol Head Neck Surg 41(5):309–315
Feurstein D, Kleinteich J, Heussner AH, Stemmer K, Dietrich DR (2010) Investigation of microcystin congener-dependent uptake into primary murine neurons. Environ Health Perspect 118(10):1370–1375. https://doi.org/10.1289/ehp.0901289
Filipski KK, Loos WJ, Verweij J, Sparreboom A (2008) Interaction of cisplatin with the human organic cation transporter 2. Clin Cancer Res 14(12):3875–3880. https://doi.org/10.1158/1078-0432.CCR-07-4793
Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A (2009) Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 86(4):396–402. https://doi.org/10.1038/clpt.2009.139
Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A (2010a) Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol 28(30):4562–4567. https://doi.org/10.1200/JCO.2010.30.7025
Franke RM, Kosloske AM, Lancaster CS, Filipski KK, Hu C, Zolk O, Mathijssen RH, Sparreboom A (2010b) Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase. Clin Cancer Res 16(16):4198–4206. https://doi.org/10.1158/1078-0432.CCR-10-0949
Frederiks CN, Lam SW, Guchelaar HJ, Boven E (2015) Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: a systematic review. Cancer Treat Rev 41(10):935–950. https://doi.org/10.1016/j.ctrv.2015.10.010
Fujita D, Saito Y, Nakanishi T, Tamai I (2016) Organic anion transporting polypeptide (OATP)2B1 contributes to gastrointestinal toxicity of anticancer drug SN-38, active metabolite of Irinotecan hydrochloride. Drug Metab Dispos 44(1):1–7. https://doi.org/10.1124/dmd.115.066712
Gallegos-Castorena S, Martinez-Avalos A, Mohar-Betancourt A, Guerrero-Avendano G, Zapata-Tarres M, Medina-Sanson A (2007) Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. Pediatr Hematol Oncol 24(6):403–408. https://doi.org/10.1080/08880010701451244
Giacomini KM, Yee SW, Ratain MJ, Weinshilboum RM, Kamatani N, Nakamura Y (2012) Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med 4(153):153ps118. https://doi.org/10.1126/scitranslmed.3003471
Gong IY, Kim RB (2013) Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab Pharmacokinet 28(1):4–18. https://doi.org/10.2133/dmpk.dmpk-12-rv-099
Grecco HE, Schmick M, Bastiaens PI (2011) Signaling from the living plasma membrane. Cell 144(6):897–909. https://doi.org/10.1016/j.cell.2011.01.029
Green H, Soderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EA, Peterson C (2009) Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 104(2):130–137. https://doi.org/10.1111/j.1742-7843.2008.00351.x
Gregg RW, Molepo JM, Monpetit VJ, Mikael NZ, Redmond D, Gadia M, Stewart DJ (1992) Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10(5):795–803. https://doi.org/10.1200/JCO.1992.10.5.795
Griffith DA, Jarvis SM (1996) Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1286(3):153–181
Grube M, Kock K, Oswald S, Draber K, Meissner K, Eckel L, Bohm M, Felix SB, Vogelgesang S, Jedlitschky G, Siegmund W, Warzok R, Kroemer HK (2006) Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther 80(6):607–620. https://doi.org/10.1016/j.clpt.2006.09.010
Grube M, Ameling S, Noutsias M, Kock K, Triebel I, Bonitz K, Meissner K, Jedlitschky G, Herda LR, Reinthaler M, Rohde M, Hoffmann W, Kuhl U, Schultheiss HP, Volker U, Felix SB, Klingel K, Kandolf R, Kroemer HK (2011) Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy. Am J Pathol 178(6):2547–2559. https://doi.org/10.1016/j.ajpath.2011.02.020
Gui C, Miao Y, Thompson L, Wahlgren B, Mock M, Stieger B, Hagenbuch B (2008) Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol 584(1):57–65. https://doi.org/10.1016/j.ejphar.2008.01.042
Gui C, Wahlgren B, Lushington GH, Hagenbuch B (2009) Identification, Ki determination and CoMFA analysis of nuclear receptor ligands as competitive inhibitors of OATP1B1-mediated estradiol-17beta-glucuronide transport. Pharmacol Res 60(1):50–56. https://doi.org/10.1016/j.phrs.2009.03.004
Hagenbuch B (2010) Drug uptake systems in liver and kidney: a historic perspective. Clin Pharmacol Ther 87(1):39–47. https://doi.org/10.1038/clpt.2009.235
Hanafy S, El-Kadi AO, Jamali F (2012) Effect of inflammation on molecular targets and drug transporters. J Pharm Pharm Sci 15(3):361–375
Hassan OT, Hassan RT, Arora RR (2016) Organic cation transporter-mediated clearance of cardiovascular drugs: a pharmacological perspective. Am J Ther 23(3):e855–e861. https://doi.org/10.1097/MJT.0000000000000148
He L, Vasiliou K, Nebert DW (2009) Analysis and update of the human solute carrier (SLC) gene superfamily. Hum Genomics 3(2):195–206
Heckman-Stoddard BM, Gandini S, Puntoni M, Dunn BK, DeCensi A, Szabo E (2016) Repurposing old drugs to chemoprevention: the case of metformin. Semin Oncol 43(1):123–133. https://doi.org/10.1053/j.seminoncol.2015.09.009
Hediger MA, Clemencon B, Burrier RE, Bruford EA (2013) The ABCs of membrane transporters in health and disease (SLC series): introduction. Mol Asp Med 34(2–3):95–107. https://doi.org/10.1016/j.mam.2012.12.009
Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, Cohen GI, Emami B, Gradishar WJ, Mitchell RB, Thigpen JT, Trotti A 3rd, von Hoff D, Schuchter LM (2009) American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 27(1):127–145. https://doi.org/10.1200/JCO.2008.17.2627
Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL, American Society of Clinical Oncology (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32(18):1941–1967. https://doi.org/10.1200/JCO.2013.54.0914
Hertz DL (2013) Germline pharmacogenetics of paclitaxel for cancer treatment. Pharmacogenomics 14(9):1065–1084. https://doi.org/10.2217/pgs.13.90
Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, Dees EC (2012) CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat 134(1):401–410. https://doi.org/10.1007/s10549-012-2054-0
Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, Dees EC (2013) CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol 24(6):1472–1478. https://doi.org/10.1093/annonc/mdt018
Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Maelandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A (2014) Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 4(9):998–1013. https://doi.org/10.1158/2159-8290.CD-14-0001
Higgins JW, Bedwell DW, Zamek-Gliszczynski MJ (2012) Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. Drug Metab Dispos 40(6):1170–1177. https://doi.org/10.1124/dmd.112.044875
Holbeck SL, Camalier R, Crowell JA, Govindharajulu JP, Hollingshead MG, Anderson LW, Polley EC, Rubinstein L, Srivastava AK, Wilsker DF, Collins JM, Doroshow JH (2017) The National Cancer Institute ALMANAC: a comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-17-0489
Holmes J, Stanko J, Varchenko M, Ding H, Madden VJ, Bagnell CR, Wyrick SD, Chaney SG (1998) Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci 46(2):342–351. https://doi.org/10.1006/toxs.1998.2558
Hosoyamada M, Sekine T, Kanai Y, Endou H (1999) Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Phys 276(1):F122–F128. https://doi.org/10.1152/ajprenal.1999.276.1.F122
Hu S, Sprowl JA (2018) Strategies to reduce solute carrier-mediated toxicity. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.1185
Hu S, Leblanc AF, Gibson AA, Hong KW, Kim JY, Janke LJ, Li L, Vasilyeva A, Finkelstein DB, Sprowl JA, Sweet DH, Schlatter E, Ciarimboli G, Schellens J, Baker SD, Pabla N, Sparreboom A (2017) Identification of OAT1/OAT3 as contributors to cisplatin toxicity. Clin Transl Sci 10(5):412–420. https://doi.org/10.1111/cts.12480
Hucke A, Rinschen MM, Bauer OB, Sperling M, Karst U, Koppen C, Sommer K, Schroter R, Ceresa C, Chiorazzi A, Canta A, Semperboni S, Marmiroli P, Cavaletti G, Schlatt S, Schlatter E, Pavenstadt H, Heitplatz B, Van Marck V, Sparreboom A, Barz V, Knief A, Deuster D, Zehnhoff-Dinnesen AA, Ciarimboli G (2019) An integrative approach to cisplatin chronic toxicities in mice reveals importance of organic cation-transporter-dependent protein networks for renoprotection. Arch Toxicol 93(10):2835–2848. https://doi.org/10.1007/s00204-019-02557-9
Hwang YY, Trendell-Smith NJ, Yeung CK, Kwong YL (2012) Fatal palmar-plantar erythrodysesthesia after clofarabine and cytarabine chemotherapy. Acta Haematol 128(3):151–153. https://doi.org/10.1159/000338828
Inaba H, Rubnitz JE, Coustan-Smith E, Li L, Furmanski BD, Mascara GP, Heym KM, Christensen R, Onciu M, Shurtleff SA, Pounds SB, Pui CH, Ribeiro RC, Campana D, Baker SD (2011) Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol 29(24):3293–3300. https://doi.org/10.1200/JCO.2011.34.7427
Innocenti F, Schilsky RL, Ramirez J, Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, Karrison T, Maitland ML, Salgia R, Ratain MJ (2014) Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol 32(22):2328–2334. https://doi.org/10.1200/JCO.2014.55.2307
International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215–236. https://doi.org/10.1038/nrd3028
Ip V, Liu JJ, McKeage MJ (2013) Evaluation of effects of copper histidine on copper transporter 1-mediated accumulation of platinum and oxaliplatin-induced neurotoxicity in vitro and in vivo. Clin Exp Pharmacol Physiol 40(6):371–378. https://doi.org/10.1111/1440-1681.12088
Ito S, Kusuhara H, Yokochi M, Toyoshima J, Inoue K, Yuasa H, Sugiyama Y (2012) Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther 340(2):393–403. https://doi.org/10.1124/jpet.111.184986
Iusuf D, van de Steeg E, Schinkel AH (2012) Hepatocyte hopping of OATP1B substrates contributes to efficient hepatic detoxification. Clin Pharmacol Ther 92(5):559–562. https://doi.org/10.1038/clpt.2012.143
Iusuf D, Ludwig M, Elbatsh A, van Esch A, van de Steeg E, Wagenaar E, van der Valk M, Lin F, van Tellingen O, Schinkel AH (2014) OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice. Mol Cancer Ther 13(2):492–503. https://doi.org/10.1158/1535-7163.Mct-13-0541
Iusuf D, Hendrikx JJ, van Esch A, van de Steeg E, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH (2015) Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel. Int J Cancer 136(1):225–233. https://doi.org/10.1002/ijc.28970
Iwata D, Kato Y, Wakayama T, Sai Y, Kubo Y, Iseki S, Tsuji A (2008) Involvement of carnitine/organic cation transporter OCTN2 (SLC22A5) in distribution of its substrate carnitine to the heart. Drug Metab Pharmacokinet 23(3):207–215
Izumi S, Nozaki Y, Kusuhara H, Hotta K, Mochizuki T, Komori T, Maeda K, Sugiyama Y (2018) Relative activity factor (RAF)-based scaling of uptake clearance mediated by organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 in human hepatocytes. Mol Pharm. https://doi.org/10.1021/acs.molpharmaceut.8b00138
Jacobs C, Coleman CN, Rich L, Hirst K, Weiner MW (1984) Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid. Cancer Res 44(8):3632–3635
Jain L, Gardner ER, Figg WD, Chernick MS, Kong HH (2010) Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction. Pharmacotherapy 30(1):52–56. https://doi.org/10.1592/phco.30.1.52
Jamieson SM, Liu J, Connor B, McKeage MJ (2005) Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother Pharmacol 56(4):391–399. https://doi.org/10.1007/s00280-004-0953-4
Jensen JB, Sundelin EI, Jakobsen S, Gormsen LC, Munk OL, Frokiaer J, Jessen N (2016) [11C]-metformin distribution in the liver and small intestine using dynamic PET in mice demonstrates tissue-specific transporter dependency. Diabetes. https://doi.org/10.2337/db16-0032
Joerger M, van Schaik RH, Becker ML, Hayoz S, Pollak M, Cathomas R, Winterhalder R, Gillessen S, Rothermundt C (2015) Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). Prostate Cancer Prostatic Dis 18(2):167–172. https://doi.org/10.1038/pcan.2015.8
Jong NN, Nakanishi T, Liu JJ, Tamai I, McKeage MJ (2011) Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons. J Pharmacol Exp Ther 338(2):537–547. https://doi.org/10.1124/jpet.111.181297
Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit JW, Schinkel AH (2001) Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol 21(16):5471–5477. https://doi.org/10.1128/MCB.21.16.5471-5477.2001
Jonker JW, Wagenaar E, Van Eijl S, Schinkel AH (2003) Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol 23(21):7902–7908
Kaback HR, Sahin-Toth M, Weinglass AB (2001) The kamikaze approach to membrane transport. Nat Rev Mol Cell Biol 2(8):610–620. https://doi.org/10.1038/35085077
Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R (2006) Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12(24):7271–7278. https://doi.org/10.1158/1078-0432.CCR-06-1249
Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K (2005) Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 20(5):379–386
Kitamura Y, Kusuhara H, Sugiyama Y (2010) Functional characterization of multidrug resistance-associated protein 3 (mrp3/abcc3) in the basolateral efflux of glucuronide conjugates in the mouse small intestine. J Pharmacol Exp Ther 332(2):659–666. https://doi.org/10.1124/jpet.109.156943
Klein J, Bentur Y, Cheung D, Moselhy G, Koren G (1991) Renal handling of cisplatin: interactions with organic anions and cations in the dog. Clin Invest Med 14(5):388–394
Kobayashi D, Aizawa S, Maeda T, Tsuboi I, Yabuuchi H, Nezu J, Tsuji A, Tamai I (2004) Expression of organic cation transporter OCTN1 in hematopoietic cells during erythroid differentiation. Exp Hematol 32(12):1156–1162. https://doi.org/10.1016/j.exphem.2004.08.009
Koepsell H (2015) Role of organic cation transporters in drug-drug interaction. Expert Opin Drug Metab Toxicol 11(10):1619–1633. https://doi.org/10.1517/17425255.2015.1069274
Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA (2001) Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 19(1):191–196. https://doi.org/10.1200/JCO.2001.19.1.191
Kubo Y, Shimizu Y, Kusagawa Y, Akanuma S, Hosoya K (2013) Propranolol transport across the inner blood-retinal barrier: potential involvement of a novel organic cation transporter. J Pharm Sci 102(9):3332–3342. https://doi.org/10.1002/jps.23535
Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H (1999) Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem 274(19):13675–13680
Lam SW, Frederiks CN, van der Straaten T, Honkoop AH, Guchelaar HJ, Boven E (2016) Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients. Br J Cancer 115(11):1335–1342. https://doi.org/10.1038/bjc.2016.326
Lancaster CS, Sprowl JA, Walker AL, Hu S, Gibson AA, Sparreboom A (2013) Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. Mol Cancer Ther 12(8):1537–1544. https://doi.org/10.1158/1535-7163.MCT-12-0926
Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O (2013) Understanding platinum-induced ototoxicity. Trends Pharmacol Sci 34(8):458–469. https://doi.org/10.1016/j.tips.2013.05.006
Lanvers-Kaminsky C, Sprowl JA, Malath I, Deuster D, Eveslage M, Schlatter E, Mathijssen RH, Boos J, Jurgens H, Am Zehnhoff-Dinnesen AG, Sparreboom A, Ciarimboli G (2015) Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity. Pharmacogenomics 16(4):323–332. https://doi.org/10.2217/pgs.14.182
Leblanc AF, Sprowl JA, Alberti P, Chiorazzi A, Arnold WD, Gibson AA, Hong KW, Pioso MS, Chen M, Huang KM, Chodisetty V, Costa O, Florea T, de Bruijn P, Mathijssen RH, Reinbolt RE, Lustberg MB, Sucheston-Campbell LE, Cavaletti G, Sparreboom A, Hu S (2018) OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. J Clin Invest 128(2):816–825. https://doi.org/10.1172/JCI96160
Lee HH, Leake BF, Teft W, Tirona RG, Kim RB, Ho RH (2015) Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance. Mol Cancer Ther 14(4):994–1003. https://doi.org/10.1158/1535-7163.MCT-14-0547
Lee HH, Leake BF, Kim RB, Ho RH (2017) Contribution of organic anion-transporting polypeptides 1A/1B to doxorubicin uptake and clearance. Mol Pharmacol 91(1):14–24. https://doi.org/10.1124/mol.116.105544
Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich EJ (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96(2):133–139
Leibbrandt ME, Wolfgang GH, Metz AL, Ozobia AA, Haskins JR (1995) Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int 48(3):761–770
Leskela S, Jara C, Leandro-Garcia LJ, Martinez A, Garcia-Donas J, Hernando S, Hurtado A, Vicario JC, Montero-Conde C, Landa I, Lopez-Jimenez E, Cascon A, Milne RL, Robledo M, Rodriguez-Antona C (2011) Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 11(2):121–129. https://doi.org/10.1038/tpj.2010.13
Letschert K, Faulstich H, Keller D, Keppler D (2006) Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci 91(1):140–149. https://doi.org/10.1093/toxsci/kfj141
Li S, Chen Y, Zhang S, More SS, Huang X, Giacomini KM (2011) Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine)chloroplatinum(II) and oxaliplatin in mice. Pharm Res 28(3):610–625. https://doi.org/10.1007/s11095-010-0312-6
Li Q, Guo D, Dong Z, Zhang W, Zhang L, Huang SM, Polli JE, Shu Y (2013) Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). Toxicol Appl Pharmacol 273(1):100–109. https://doi.org/10.1016/j.taap.2013.08.024
Lionetti V, Ventura C (2013) Regenerative medicine approach to repair the failing heart. Vasc Pharmacol 58(3):159–163. https://doi.org/10.1016/j.vph.2013.01.002
Lipka DB, Wagner MC, Dziadosz M, Schnoder T, Heidel F, Schemionek M, Melo JV, Kindler T, Muller-Tidow C, Koschmieder S, Fischer T (2012) Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells. PLoS One 7(7):e40853. https://doi.org/10.1371/journal.pone.0040853
Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT, Hudson MM, Kremer LC, Landy DC, Miller TL, Oeffinger KC, Rosenthal DN, Sable CA, Sallan SE, Singh GK, Steinberger J, Cochran TR, Wilkinson JD (2013) Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 128(17):1927–1995. https://doi.org/10.1161/CIR.0b013e3182a88099
Lipworth AD, Robert C, Zhu AX (2009) Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 77(5):257–271. https://doi.org/10.1159/000258880
Lu R, Chan BS, Schuster VL (1999) Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Phys 276(2):F295–F303. https://doi.org/10.1152/ajprenal.1999.276.2.F295
Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A (2015) Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol 72(2):221–236. https://doi.org/10.1016/j.jaad.2014.07.033
Maniez-Devos DM, Baurain R, Lesne M, Trouet A (1986) Doxorubicin and daunorubicin plasmatic, hepatic and renal disposition in the rabbit with or without enterohepatic circulation. J Pharmacol 17(1):1–13
Marada VV, Florl S, Kuhne A, Burckhardt G, Hagos Y (2015) Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds. Eur J Med Chem 92:723–731. https://doi.org/10.1016/j.ejmech.2015.01.011
Marmiroli P, Cavaletti G (2016) Drugs for the treatment of peripheral neuropathies. Expert Opin Pharmacother 17(3):381–394. https://doi.org/10.1517/14656566.2016.1120719
McBride BF, Yang T, Liu K, Urban TJ, Giacomini KM, Kim RB, Roden DM (2009) The organic cation transporter, OCTN1, expressed in the human heart, potentiates antagonism of the HERG potassium channel. J Cardiovasc Pharmacol 54(1):63–71. https://doi.org/10.1097/FJC.0b013e3181abc288
McCreight LJ, Bailey CJ, Pearson ER (2016) Metformin and the gastrointestinal tract. Diabetologia 59(3):426–435. https://doi.org/10.1007/s00125-015-3844-9
McKeage MJ, Hsu T, Screnci D, Haddad G, Baguley BC (2001) Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 85(8):1219–1225. https://doi.org/10.1054/bjoc.2001.2024
McWhinney SR, Goldberg RM, McLeod HL (2009) Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 8(1):10–16. https://doi.org/10.1158/1535-7163.MCT-08-0840
Medwid S, Li MMJ, Knauer MJ, Lin K, Mansell SE, Schmerk CL, Zhu C, Griffin KE, Yousif MD, Dresser GK, Schwarz UI, Kim RB, Tirona RG (2019) Fexofenadine and rosuvastatin pharmacokinetics in mice with targeted disruption of organic anion transporting polypeptide 2B1. Drug Metab Dispos 47(8):832–842. https://doi.org/10.1124/dmd.119.087619
Mielke S, Sparreboom A, Mross K (2006) Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 42(1):24–30. https://doi.org/10.1016/j.ejca.2005.06.030
Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K (2004) Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol 503(1–3):25–30. https://doi.org/10.1016/j.ejphar.2004.09.032
Murray AW (1971) The biological significance of purine salvage. Annu Rev Biochem 40:811–826. https://doi.org/10.1146/annurev.bi.40.070171.004115
Nakamura T, Yonezawa A, Hashimoto S, Katsura T, Inui K (2010) Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol 80(11):1762–1767. https://doi.org/10.1016/j.bcp.2010.08.019
Ni W, Ji J, Dai Z, Papp A, Johnson AJ, Ahn S, Farley KL, Lin TS, Dalton JT, Li X, Jarjoura D, Byrd JC, Sadee W, Grever MR, Phelps MA (2010) Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One 5(11):e13792. https://doi.org/10.1371/journal.pone.0013792
Nieuweboer AJ, Hu S, Gui C, Hagenbuch B, Ghobadi Moghaddam-Helmantel IM, Gibson AA, de Bruijn P, Mathijssen RH, Sparreboom A (2014) Influence of drug formulation on OATP1B-mediated transport of paclitaxel. Cancer Res 74(11):3137–3145. https://doi.org/10.1158/0008-5472.CAN-13-3634
Nigam SK (2015) What do drug transporters really do? Nat Rev Drug Discov 14(1):29–44. https://doi.org/10.1038/nrd4461
Nishida K, Takeuchi K, Hosoda A, Sugano S, Morisaki E, Ohishi A, Nagasawa K (2018) Ergothioneine ameliorates oxaliplatin-induced peripheral neuropathy in rats. Life Sci 207:516–524. https://doi.org/10.1016/j.lfs.2018.07.006
Nishimura M, Naito S (2008) Tissue-specific mRNA expression profiles of human solute carrier transporter superfamilies. Drug Metab Pharmacokinet 23(1):22–44
Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I (2005) Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33(3):434–439. https://doi.org/10.1124/dmd.104.001909
Okabe M, Unno M, Harigae H, Kaku M, Okitsu Y, Sasaki T, Mizoi T, Shiiba K, Takanaga H, Terasaki T, Matsuno S, Sasaki I, Ito S, Abe T (2005) Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun 333(3):754–762. https://doi.org/10.1016/j.bbrc.2005.05.174
Okabe M, Szakacs G, Reimers MA, Suzuki T, Hall MD, Abe T, Weinstein JN, Gottesman MM (2008) Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 7(9):3081–3091. https://doi.org/10.1158/1535-7163.MCT-08-0539
Omlin A, Sartor O, Rothermundt C, Cathomas R, De Bono JS, Shen L, Su Z, Gillessen S (2015) Analysis of side effect profile of alopecia, nail changes, peripheral neuropathy, and dysgeusia in prostate cancer patients treated with docetaxel and cabazitaxel. Clin Genitourin Cancer 13(4):e205–e208. https://doi.org/10.1016/j.clgc.2015.01.010
Osman NM, Litterst CL (1983) Effect of probenecid and N’-methylnicotinamide on renal handling of cis-dichlorodiammineplatinum-II in rats. Cancer Lett 19(1):107–111
Ota K, Ito K, Akahira J, Sato N, Onogawa T, Moriya T, Unno M, Abe T, Niikura H, Takano T, Yaegashi N (2007) Expression of organic cation transporter SLC22A16 in human epithelial ovarian cancer: a possible role of the adriamycin importer. Int J Gynecol Pathol 26(3):334–340. https://doi.org/10.1097/01.pgp.0000236951.33914.1b
Owens JK, Shewach DS, Ullman B, Mitchell BS (1992) Resistance to 1-β-d-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res 52(9):2389–2393
Pabla N, Gibson AA, Buege M, Ong SS, Li L, Hu S, Du G, Sprowl JA, Vasilyeva A, Janke LJ, Schlatter E, Chen T, Ciarimboli G, Sparreboom A (2015) Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. Proc Natl Acad Sci U S A 112(16):5231–5236. https://doi.org/10.1073/pnas.1424313112
Pawlyk AC, Giacomini KM, McKeon C, Shuldiner AR, Florez JC (2014) Metformin pharmacogenomics: current status and future directions. Diabetes 63(8):2590–2599. https://doi.org/10.2337/db13-1367
Peters CM, Jimenez-Andrade JM, Jonas BM, Sevcik MA, Koewler NJ, Ghilardi JR, Wong GY, Mantyh PW (2007) Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol 203(1):42–54. https://doi.org/10.1016/j.expneurol.2006.07.022
Price PM, Safirstein RL, Megyesi J (2009) The cell cycle and acute kidney injury. Kidney Int 76(6):604–613. https://doi.org/10.1038/ki.2009.224
Raghunand N, He X, van Sluis R, Mahoney B, Baggett B, Taylor CW, Paine-Murrieta G, Roe D, Bhujwalla ZM, Gillies RJ (1999) Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 80(7):1005–1011. https://doi.org/10.1038/sj.bjc.6690455
Robert J, Vrignaud P, Nguyen-Ngoc T, Iliadis A, Mauriac L, Hurteloup P (1985) Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer. Cancer Treat Rep 69(6):633–640
Robert J, Bui NB, Vrignaud P (1987) Pharmacokinetics of doxorubicin in sarcoma patients. Eur J Clin Pharmacol 31(6):695–699
Ross DA, Gale GR (1979) Reduction of the renal toxicity of cis-dichlorodiammineplatinum(II) by probenecid. Cancer Treat Rep 63(5):781–787
Safirstein R, Miller P, Guttenplan JB (1984) Uptake and metabolism of cisplatin by rat kidney. Kidney Int 25(5):753–758
Salphati L, Chu X, Chen L, Prasad B, Dallas S, Evers R, Mamaril-Fishman D, Geier EG, Kehler J, Kunta J, Mezler M, Laplanche L, Pang J, Rode A, Soars MG, Unadkat JD, van Waterschoot RA, Yabut J, Schinkel AH, Scheer N (2014) Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins. Drug Metab Dispos 42(8):1301–1313. https://doi.org/10.1124/dmd.114.057976
Sastry J, Kellie SJ (2005) Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol 22(5):441–445. https://doi.org/10.1080/08880010590964381
Sayed-Ahmed MM, Al-Shabanah OA, Hafez MM, Aleisa AM, Al-Rejaie SS (2010) Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model. Eur J Pharmacol 640(1–3):143–149. https://doi.org/10.1016/j.ejphar.2010.05.002
Schneider BP, Hershman DL, Loprinzi C (2015a) Symptoms: chemotherapy-induced peripheral neuropathy. Adv Exp Med Biol 862:77–87. https://doi.org/10.1007/978-3-319-16366-6_6
Schneider BP, Li L, Radovich M, Shen F, Miller KD, Flockhart DA, Jiang G, Vance G, Gardner L, Vatta M, Bai S, Lai D, Koller D, Zhao F, O’Neill A, Smith ML, Railey E, White C, Partridge A, Sparano J, Davidson NE, Foroud T, Sledge GW Jr (2015b) Genome-wide association studies for taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res 21(22):5082–5091. https://doi.org/10.1158/1078-0432.CCR-15-0586
Scripture CD, Figg WD, Sparreboom A (2006) Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol 4(2):165–172
Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117(5):1422–1431. https://doi.org/10.1172/JCI30558
Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339(13):900–905. https://doi.org/10.1056/NEJM199809243391307
Singer SJ, Nicolson GL (1972) The fluid mosaic model of the structure of cell membranes. Science 175(4023):720–731
Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, Mielke S (2006) Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 42(17):2893–2896. https://doi.org/10.1016/j.ejca.2006.06.017
Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A (2005) Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 4(8):815–818
Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, Figg WD, Verweij J, McLeod HL, Sparreboom A (2007) Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 81(1):76–82. https://doi.org/10.1038/sj.clpt.6100011
Song IH, Zong J, Borland J, Jerva F, Wynne B, Zamek-Gliszczynski MJ, Humphreys JE, Bowers GD, Choukour M (2016) The effect of Dolutegravir on the pharmacokinetics of metformin in healthy subjects. J Acquir Immune Defic Syndr. https://doi.org/10.1097/QAI.0000000000000983
Sparreboom A, Huizing MT, Boesen JJ, Nooijen WJ, van Tellingen O, Beijnen JH (1995) Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces. Cancer Chemother Pharmacol 36(4):299–304. https://doi.org/10.1007/BF00689047
Sprowl JA, Sparreboom A (2014) Uptake carriers and oncology drug safety. Drug Metab Dispos 42(4):611–622. https://doi.org/10.1124/dmd.113.055806
Sprowl JA, Ciarimboli G, Lancaster CS, Giovinazzo H, Gibson AA, Du G, Janke LJ, Cavaletti G, Shields AF, Sparreboom A (2013a) Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A 110(27):11199–11204. https://doi.org/10.1073/pnas.1305321110
Sprowl JA, Mathijssen RH, Sparreboom A (2013b) Can erlotinib ameliorate cisplatin-induced toxicities? J Clin Oncol 31(27):3442–3443. https://doi.org/10.1200/JCO.2013.50.8184
Sprowl JA, Ness RA, Sparreboom A (2013c) Polymorphic transporters and platinum pharmacodynamics. Drug Metab Pharmacokinet 28(1):19–27. https://doi.org/10.2133/dmpk.dmpk-12-rv-073
Sprowl JA, Lancaster CS, Pabla N, Hermann E, Kosloske AM, Gibson AA, Li L, Zeeh D, Schlatter E, Janke LJ, Ciarimboli G, Sparreboom A (2014) Cisplatin-induced renal injury is independently mediated by OCT2 and p53. Clin Cancer Res 20(15):4026–4035. https://doi.org/10.1158/1078-0432.CCR-14-0319
Sprowl JA, Ong SS, Gibson AA, Hu S, Du G, Lin W, Li L, Bharill S, Ness RA, Stecula A, Offer SM, Diasio RB, Nies AT, Schwab M, Cavaletti G, Schlatter E, Ciarimboli G, Schellens JH, Isacoff EY, Sali A, Chen T, Baker SD, Sparreboom A, Pabla N (2016) A phosphotyrosine switch regulates organic cation transporters. Nat Commun 7:10880. https://doi.org/10.1038/ncomms10880
Stage TB, Brosen K, Christensen MM (2015a) A comprehensive review of drug-drug interactions with metformin. Clin Pharmacokinet 54(8):811–824. https://doi.org/10.1007/s40262-015-0270-6
Stage TB, Damkier P, Pedersen RS, Christensen MM, Christiansen L, Christensen K, Brosen K (2015b) A twin study of the trough plasma steady-state concentration of metformin. Pharmacogenet Genomics 25(5):259–262. https://doi.org/10.1097/FPC.0000000000000133
Stage TB, Lee MP, Hallas J, Christensen MM, Brosen K, Christensen K, Gagne JJ, Pottegard A (2016) Early discontinuation of metformin in individuals treated with inhibitors of transporters of metformin. Basic Clin Pharmacol Toxicol 118(6):487–495. https://doi.org/10.1111/bcpt.12579
Sucheston LE, Zhao H, Yao S, Zirpoli G, Liu S, Barlow WE, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, Hayes DF, Ambrosone CB (2011) Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat 130(3):993–1002. https://doi.org/10.1007/s10549-011-1671-3
Sun X, Li J, Guo C, Xing H, Xu J, Wen Y, Qiu Z, Zhang Q, Zheng Y, Chen X, Zhao D (2016) Pharmacokinetic effects of curcumin on docetaxel mediated by OATP1B1, OATP1B3 and CYP450s. Drug Metab Pharmacokinet 31(4):269–275. https://doi.org/10.1016/j.dmpk.2016.02.005
Svoboda M, Wlcek K, Taferner B, Hering S, Stieger B, Tong D, Zeillinger R, Thalhammer T, Jager W (2011) Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. Biomed Pharmacother 65(6):417–426. https://doi.org/10.1016/j.biopha.2011.04.031
Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97(11):2869–2879. https://doi.org/10.1002/cncr.11407
Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A (2000) Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273(1):251–260. https://doi.org/10.1006/bbrc.2000.2922
Tanabe Y, Shimizu C, Hamada A, Hashimoto K, Ikeda K, Nishizawa D, Hasegawa J, Shimomura A, Ozaki Y, Tamura N, Yamamoto H, Yunokawa M, Yonemori K, Takano T, Kawabata H, Tamura K, Fujiwara Y (2017) Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. Cancer Chemother Pharmacol 79(6):1179–1186. https://doi.org/10.1007/s00280-017-3314-9
Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC (1984) Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 54(7):1269–1275
Tian A, Lu H, Zhang J, Fu S, Jiang Z, Lam W, Guan F, Chen L, Feng L, Cheng Y (2018) Multikinase inhibitor sorafenib induces skin toxicities in tumor-bearing mice. Cancer Chemother Pharmacol 81(6):1025–1033. https://doi.org/10.1007/s00280-018-3575-y
Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, Feldman DR, Pagliaro LC, Miller RC, Vaughn DJ, Einhorn LH, Cox NJ, Dolan ME (2014) Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst 106(5). https://doi.org/10.1093/jnci/dju044
Tregouet DA, Konig IR, Erdmann J, Munteanu A, Braund PS, Hall AS, Grosshennig A, Linsel-Nitschke P, Perret C, DeSuremain M, Meitinger T, Wright BJ, Preuss M, Balmforth AJ, Ball SG, Meisinger C, Germain C, Evans A, Arveiler D, Luc G, Ruidavets JB, Morrison C, van der Harst P, Schreiber S, Neureuther K, Schafer A, Bugert P, El Mokhtari NE, Schrezenmeir J, Stark K, Rubin D, Wichmann HE, Hengstenberg C, Ouwehand W, Wellcome Trust Case Control Consortium, Cardiogenics Consortium, Ziegler A, Tiret L, Thompson JR, Cambien F, Schunkert H, Samani NJ (2009) Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 41(3):283–285. https://doi.org/10.1038/ng.314
Trevisan G, Materazzi S, Fusi C, Altomare A, Aldini G, Lodovici M, Patacchini R, Geppetti P, Nassini R (2013) Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade. Cancer Res 73(10):3120–3131. https://doi.org/10.1158/0008-5472.CAN-12-4370
Tschirka J, Kreisor M, Betz J, Grundemann D (2018) Substrate selectivity check of the ergothioneine transporter. Drug Metab Dispos 46(6):779–785. https://doi.org/10.1124/dmd.118.080440
Tsuda M, Terada T, Mizuno T, Katsura T, Shimakura J, Inui K (2009) Targeted disruption of the multidrug and toxin extrusion 1 (MATE1) gene in mice reduces renal secretion of metformin. Mol Pharmacol 75(6):1280–1286. https://doi.org/10.1124/mol.109.056242
Urban TJ, Yang C, Lagpacan LL, Brown C, Castro RA, Taylor TR, Huang CC, Stryke D, Johns SJ, Kawamoto M, Carlson EJ, Ferrin TE, Burchard EG, Giacomini KM (2007) Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenet Genomics 17(9):773–782. https://doi.org/10.1097/FPC.0b013e3281c6d08e
Vallon V, Rieg T, Ahn SY, Wu W, Eraly SA, Nigam SK (2008) Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol 294(4):F867–F873. https://doi.org/10.1152/ajprenal.00528.2007
van de Steeg E, van Esch A, Wagenaar E, van der Kruijssen CM, van Tellingen O, Kenworthy KE, Schinkel AH (2011) High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin Cancer Res 17(2):294–301. https://doi.org/10.1158/1078-0432.CCR-10-1980
van de Steeg E, van Esch A, Wagenaar E, Kenworthy KE, Schinkel AH (2013) Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin Cancer Res 19(4):821–832. https://doi.org/10.1158/1078-0432.CCR-12-2080
VanWert AL, Gionfriddo MR, Sweet DH (2010) Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos 31(1):1–71. https://doi.org/10.1002/bdd.693
Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91(5):710–717
Waissbluth S, Daniel SJ (2013) Cisplatin-induced ototoxicity: transporters playing a role in cisplatin toxicity. Hear Res 299:37–45. https://doi.org/10.1016/j.heares.2013.02.002
Wang L, Weinshilboum R (2014) Metformin pharmacogenomics: biomarkers to mechanisms. Diabetes 63(8):2609–2610. https://doi.org/10.2337/db14-0609
Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y (2002) Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 302(2):510–515. https://doi.org/10.1124/jpet.102.034140
Wang L, Chen J, Zeng Y, Wei J, Jing J, Li G, Su L, Tang X, Wu T, Zhou L (2016) Functional variant in the SLC22A3-LPAL2-LPA gene cluster contributes to the severity of coronary artery disease. Arterioscler Thromb Vasc Biol 36(9):1989–1996. https://doi.org/10.1161/ATVBAHA.116.307311
Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V (2000) Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta 1466(1–2):315–327
Xia B, Heimbach T, He H, Lin TH (2012) Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability. Biopharm Drug Dispos 33(9):536–549. https://doi.org/10.1002/bdd.1821
Yamada S, Arrell DK, Martinez-Fernandez A, Behfar A, Kane GC, Perez-Terzic CM, Crespo-Diaz RJ, McDonald RJ, Wyles SP, Zlatkovic-Lindor J, Nelson TJ, Terzic A (2015) Regenerative therapy prevents heart failure progression in dyssynchronous nonischemic narrow QRS cardiomyopathy. J Am Heart Assoc 4(5). https://doi.org/10.1161/JAHA.114.001614
Yamaguchi H, Kobayashi M, Okada M, Takeuchi T, Unno M, Abe T, Goto J, Hishinuma T, Mano N (2008) Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett 260(1–2):163–169. https://doi.org/10.1016/j.canlet.2007.10.040
Yan X, Maixner DW, Yadav R, Gao M, Li P, Bartlett MG, Weng HR (2015) Paclitaxel induces acute pain via directly activating toll like receptor 4. Mol Pain 11:10. https://doi.org/10.1186/s12990-015-0005-6
Yang X, Han L (2019) Roles of renal drug transporter in drug disposition and renal toxicity. Adv Exp Med Biol 1141:341–360. https://doi.org/10.1007/978-981-13-7647-4_7
Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334(2):115–124. https://doi.org/10.1097/MAJ.0b013e31812dfe1e
Yokoo S, Masuda S, Yonezawa A, Terada T, Katsura T, Inui K (2008) Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab Dispos 36(11):2299–2306. https://doi.org/10.1124/dmd.108.023168
Zaher H, Meyer zu Schwabedissen HE, Tirona RG, Cox ML, Obert LA, Agrawal N, Palandra J, Stock JL, Kim RB, Ware JA (2008) Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol 74(2):320–329. https://doi.org/10.1124/mol.108.046458
Zhang J, Zhou W (2012) Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. Food Chem Toxicol 50(7):2289–2293. https://doi.org/10.1016/j.fct.2012.03.077
Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, Lippard SJ, Giacomini KM (2006) Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 66(17):8847–8857. https://doi.org/10.1158/0008-5472.CAN-06-0769
Zhang B, Bolognia J, Marks P, Podoltsev N (2014) Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia. Cancer Chemother Pharmacol 74(2):303–307. https://doi.org/10.1007/s00280-014-2504-y
Zhao M, Isami K, Nakamura S, Shirakawa H, Nakagawa T, Kaneko S (2012) Acute cold hypersensitivity characteristically induced by oxaliplatin is caused by the enhanced responsiveness of TRPA1 in mice. Mol Pain 8:55. https://doi.org/10.1186/1744-8069-8-55
Zhu HJ, Appel DI, Grundemann D, Richelson E, Markowitz JS (2012) Evaluation of organic cation transporter 3 (SLC22A3) inhibition as a potential mechanism of antidepressant action. Pharmacol Res 65(4):491–496. https://doi.org/10.1016/j.phrs.2012.01.008
Zimmerman EI, Hu S, Roberts JL, Gibson AA, Orwick SJ, Li L, Sparreboom A, Baker SD (2013) Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res 19(6):1458–1466. https://doi.org/10.1158/1078-0432.CCR-12-3306
Zimmerman EI, Gibson AA, Hu S, Vasilyeva A, Orwick SJ, Du G, Mascara GP, Ong SS, Chen T, Vogel P, Inaba H, Maitland ML, Sparreboom A, Baker SD (2016) Multikinase inhibitors induce cutaneous toxicity through OAT6-mediated uptake and MAP 3K7-driven cell death. Cancer Res 76(1):117–126. https://doi.org/10.1158/0008-5472.CAN-15-0694
Zong J, Borland J, Jerva F, Wynne B, Choukour M, Song I (2014) The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects. J Int AIDS Soc 17(4 Suppl 3):19584. https://doi.org/10.7448/IAS.17.4.19584
Zwart R, Verhaagh S, Buitelaar M, Popp-Snijders C, Barlow DP (2001) Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice. Mol Cell Biol 21(13):4188–4196. https://doi.org/10.1128/MCB.21.13.4188-4196.2001
Acknowledgement
This work was supported in part by the National Institutes of Health Grants R01CA215802 (to A.S.), R01CA238946 (to S.H., M.B.L), and by the OSU Comprehensive Cancer Center using Pelotonia funds. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.
Conflicts of Interest
The authors have no conflicts of interests.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Anderson, J.T., Huang, K.M., Lustberg, M.B., Sparreboom, A., Hu, S. (2020). Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions. In: Stock, C., Pardo, L.A. (eds) Targets of Cancer Diagnosis and Treatment. Reviews of Physiology, Biochemistry and Pharmacology, vol 183. Springer, Cham. https://doi.org/10.1007/112_2020_30
Download citation
DOI: https://doi.org/10.1007/112_2020_30
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-03993-5
Online ISBN: 978-3-031-03994-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)